AbbVie Evaluates Vitiligo Comorbidities Using the IHD Analytics Platform

In this case study, we examine how an AbbVie research team used Panalgo’s IHD Analytics platform to evaluate comorbidities among vitiligo patients from a large U.S. commercial claims database. Vitiligo, a chronic autoimmune disorder, is a common disorder, affecting about 1 percent of the population worldwide.

In this case study, you’ll learn:

• The background of vitiligo and purpose of the study
• The methodology used to design and conduct the study
• What results and insights were gleaned
• Why sensitivity analyses are crucial and how to conduct them properly